Data updated: Nov 8, 2026
INDOMETHACIN · WATSON LABS
Pain
Approved 1982-02-23
43
Indications
--
Phase 3 Trials
44
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1982-02-23
- Routes
- ORAL, RECTAL, INJECTION
- Dosage Forms
- CAPSULE, EXTENDED RELEASE, SUSPENSION, CAPSULE, SUPPOSITORY, INJECTABLE
Companies
WATSON LABS JUBILANT GENERICS NOVITIUM PHARMA DURAMED PHARMS BARR Sun Pharma GLENMARK PHARMS LTD Aurobindo Pharma PIONEER PHARMS HERITAGE PHARMA Novartis AVANTHI INC PARKE DAVIS CYCLE HALSEY HERITAGE HETERO LABS LTD III Hikma RISING ANI PHARMS Teva ZYDUS LIFESCIENCES CHARTWELL RX ANNORA PHARMA MUTUAL PHARM SUPERPHARM INWOOD LABS ABLE Viatris AMNEAL COSETTE CHARTWELL MOLECULES AMNEAL PHARMS ZYDUS PHARMS NOVAST LABS Fresenius Kabi IVAX SUB TEVA PHARMS
Active Ingredient: INDOMETHACIN
Website: ↗
INDOMETHACIN Approval History
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
557 FDA actions from 1984 to 2026
Oct 2026 SUPPL
Label · Labeling
Sep 2026 SUPPL
Label · Labeling
Jul 2025 ORIGINAL
Update
Jun 2025 SUPPL
Label
Feb 2025 ORIGINAL
Update
Nov 2024 SUPPL
Label
Nov 2024 ORIGINAL
Update
Apr 2024 SUPPL
Label
Mar 2024 SUPPL
Label
Jan 2024 ORIGINAL
Update
Oct 2023 SUPPL
Label
Sep 2023 SUPPL
Label
Aug 2023 ORIGINAL
Update
May 2021 SUPPL
Label
May 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Apr 2021 SUPPL
Label
Feb 2020 SUPPL
Label
Nov 2019 SUPPL
Label
Sep 2019 SUPPL
Label
Sep 2019 SUPPL
Label
Aug 2019 SUPPL
Label
Aug 2017 ORIGINAL
Update
Jun 2017 ORIGINAL
Update
May 2017 ORIGINAL
Update
Dec 2016 ORIGINAL
Update
Jul 2016 SUPPL
Mfg
Jun 2016 SUPPL
Label
May 2016 SUPPL
Label
Oct 2015 ORIGINAL
Update
Jun 2015 SUPPL
Mfg
Mar 2014 ORIGINAL
Update
Dec 2013 ORIGINAL
Update
Mar 2013 ORIGINAL
Update
Sep 2012 ORIGINAL
Update
Apr 2011 SUPPL
Label
Apr 2011 ORIGINAL
Update
Dec 2010 ORIGINAL
Update
Dec 2010 ORIGINAL
Update
Nov 2010 ORIGINAL
Update
Nov 2010 ORIGINAL
Update
Mar 2009 ORIGINAL
Update
Apr 2008 SUPPL
Label
Jan 2008 SUPPL
Label
Apr 2007 SUPPL
Label
Nov 2006 SUPPL
Label
Nov 2006 SUPPL
Label
Sep 2006 SUPPL
Label
Jun 2006 SUPPL
Label
Jun 2006 SUPPL
Label
Mar 2006 SUPPL
Label
Dec 2003 ORIGINAL
Update
Nov 2002 SUPPL
Label
Sep 2002 SUPPL
Mfg
Sep 2002 SUPPL
Label
Aug 2002 SUPPL
Label
Aug 2002 SUPPL
Mfg
Aug 2002 SUPPL
Label
Jul 2002 SUPPL
Mfg
Sep 2001 SUPPL
Mfg
Jun 2001 SUPPL
Mfg
May 2001 SUPPL
Mfg
Jul 2000 SUPPL
Label
Jul 2000 SUPPL
Mfg
May 2000 SUPPL
Mfg
Apr 2000 SUPPL
Mfg
Feb 2000 SUPPL
Mfg
Jan 2000 SUPPL
Mfg
Feb 1999 SUPPL
Mfg
Dec 1998 SUPPL
Mfg
Nov 1998 SUPPL
Mfg
Apr 1998 SUPPL
Mfg
Mar 1998 SUPPL
Mfg
Feb 1998 SUPPL
Mfg
Feb 1998 SUPPL
Mfg
Dec 1997 SUPPL
Mfg
May 1997 SUPPL
Mfg
Feb 1997 SUPPL
Mfg
Jan 1997 SUPPL
Mfg
Oct 1996 SUPPL
Label
Aug 1996 SUPPL
Mfg
Jul 1996 SUPPL
Label
Jul 1996 SUPPL
Label
Jul 1996 SUPPL
Label
Jun 1996 SUPPL
Mfg
Apr 1996 SUPPL
Label
Apr 1996 SUPPL
Label
Apr 1996 SUPPL
Label
Mar 1996 SUPPL
Mfg
Dec 1995 SUPPL
Mfg
Nov 1995 SUPPL
Mfg
Jul 1995 SUPPL
Mfg
May 1995 SUPPL
Mfg
Feb 1995 SUPPL
Mfg
Dec 1994 SUPPL
Mfg
Nov 1994 SUPPL
Mfg
Oct 1994 SUPPL
Mfg
Aug 1994 SUPPL
Mfg
Jul 1994 SUPPL
Mfg
Jul 1994 SUPPL
Label
May 1994 SUPPL
Mfg
May 1994 SUPPL
Mfg
Mar 1994 SUPPL
Mfg
Feb 1994 SUPPL
Mfg
Jan 1994 SUPPL
Mfg
Oct 1993 SUPPL
Label
Aug 1993 SUPPL
Label
Apr 1993 SUPPL
Mfg
Apr 1993 SUPPL
Label
Apr 1993 SUPPL
Label
Mar 1993 SUPPL
Label
Dec 1992 SUPPL
Label
Dec 1992 SUPPL
Label
Nov 1992 SUPPL
Mfg
Nov 1992 SUPPL
Mfg
Nov 1992 SUPPL
Mfg
Sep 1992 SUPPL
Label
Aug 1992 ORIGINAL
Update
Aug 1992 SUPPL
Label
May 1992 SUPPL
Label
May 1992 SUPPL
Mfg
Apr 1992 SUPPL
Label
Apr 1992 SUPPL
Mfg
Jan 1992 SUPPL
Label
Dec 1991 SUPPL
Label
Dec 1991 SUPPL
Label
Nov 1991 SUPPL
Label
Sep 1991 SUPPL
Label
Jul 1991 ORIGINAL
Update
Jul 1991 SUPPL
Label
Jul 1991 SUPPL
Mfg
Jul 1991 SUPPL
Label
Apr 1991 SUPPL
Label
Apr 1991 SUPPL
Mfg
Apr 1991 SUPPL
Label
Jan 1991 SUPPL
Label
Dec 1990 SUPPL
Label
Sep 1990 SUPPL
Label
May 1990 SUPPL
Mfg
Feb 1990 SUPPL
Label
Jan 1990 SUPPL
Mfg
Nov 1989 SUPPL
Label
Oct 1989 SUPPL
Label
Oct 1989 SUPPL
Label
Oct 1989 SUPPL
Label
Sep 1989 SUPPL
Label
Aug 1989 SUPPL
Label
Jul 1989 SUPPL
Mfg
Jun 1989 SUPPL
Label
Jun 1989 SUPPL
Label
Jun 1989 SUPPL
Label
Jun 1989 SUPPL
Label
Jun 1989 SUPPL
Label
May 1989 SUPPL
Mfg
Apr 1989 SUPPL
Label
Mar 1989 SUPPL
Label
Mar 1989 SUPPL
Label
Mar 1989 ORIGINAL
Update
Mar 1989 SUPPL
Label
Feb 1989 SUPPL
Label
Feb 1989 SUPPL
Label
Feb 1989 SUPPL
Mfg
Feb 1989 SUPPL
Label
Feb 1989 SUPPL
Label
Jan 1989 SUPPL
Mfg
Dec 1988 SUPPL
Label
Nov 1988 SUPPL
Label
Oct 1988 SUPPL
Label
Apr 1988 ORIGINAL
Update
Apr 1988 SUPPL
Label
Apr 1988 SUPPL
Label
Mar 1988 SUPPL
Label
Mar 1988 SUPPL
Mfg
Feb 1988 SUPPL
Label
Feb 1988 SUPPL
Mfg
Nov 1987 SUPPL
Mfg
Oct 1987 SUPPL
Mfg
Sep 1987 SUPPL
Mfg
May 1987 ORIGINAL
Update
May 1987 SUPPL
Mfg
May 1987 SUPPL
Label
Apr 1987 ORIGINAL
Update
Apr 1987 SUPPL
Mfg
Mar 1987 SUPPL
Mfg
Mar 1987 SUPPL
Label
Mar 1987 ORIGINAL
Update
Feb 1987 ORIGINAL
Update
Oct 1986 SUPPL
Mfg
Oct 1986 ORIGINAL
Update
Oct 1986 ORIGINAL
Update
Sep 1986 SUPPL
Label
Aug 1986 SUPPL
Mfg
Aug 1986 SUPPL
Mfg
Jun 1986 SUPPL
Label
Apr 1986 SUPPL
Mfg
Apr 1986 SUPPL
Label
Mar 1986 SUPPL
Label
Mar 1986 ORIGINAL
Update
Feb 1986 ORIGINAL
Update
Oct 1985 SUPPL
Mfg
Oct 1985 ORIGINAL
Update
Oct 1985 SUPPL
Mfg
Sep 1985 ORIGINAL
Update
Jul 1985 SUPPL
Mfg
Jun 1985 SUPPL
Mfg
Mar 1985 SUPPL
Mfg
Aug 1984 ORIGINAL
Update
May 1984 ORIGINAL
Update
May 1984 ORIGINAL
Update
Apr 1984 ORIGINAL
Update
What INDOMETHACIN Treats
43 FDA approvalsOriginally approved for its first indication in 1984 . Covers 43 distinct patient populations.
- Other (43)
Other
(43 approvals)- • Approved indication (Apr 1984)
- • Approved indication (May 1984)
- • Approved indication (May 1984)
- • Approved indication (Aug 1984)
- • Approved indication (Sep 1985)
- • Approved indication (Oct 1985)
- • Approved indication (Feb 1986)
- • Approved indication (Mar 1986)
- • Approved indication (Oct 1986)
- • Approved indication (Oct 1986)
- • Approved indication (Feb 1987)
- • Approved indication (Mar 1987)
- • Approved indication (Apr 1987)
- • Approved indication (May 1987)
- • Approved indication (Apr 1988)
- • Approved indication (Mar 1989)
- • Approved indication (Jul 1991)
- • Approved indication (Aug 1992)
- • Approved indication (May 1998)Letter
- • Approved indication (Feb 2002)Letter
- • Approved indication (Dec 2003)
- • Approved indication (Mar 2009)
- • Approved indication (Mar 2010)Label Letter
- • Approved indication (Nov 2010)
- • Approved indication (Nov 2010)
- • Approved indication (Dec 2010)
- • Approved indication (Dec 2010)
- • Approved indication (Apr 2011)
- • Approved indication (Sep 2012)
- • Approved indication (Mar 2013)
- • Approved indication (Dec 2013)
- • Approved indication (Mar 2014)
- • Approved indication (Oct 2015)
- • Approved indication (Dec 2016)
- • Approved indication (May 2017)
- • Approved indication (Jun 2017)
- • Approved indication (Aug 2017)
- • Approved indication (Sep 2017)Letter
- • Approved indication (Aug 2023)
- • Approved indication (Jan 2024)
- • Approved indication (Nov 2024)
- • Approved indication (Feb 2025)
- • Approved indication (Jul 2025)
📋
Clinical Trial Registry
42 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02205762 | 13-428 2011-001699-20, 042011 | Ph 2, Ph 3 | active not recruiting | LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis |
| NCT02858310 results posted | 160154 16-C-0154 | Ph 1, Ph 2 | completed | E7 TCR T Cells for Human Papillomavirus-Associated Cancers |
| NCT02950259 results posted | 16-126B IRX-2 2016-B | Ph 1 | completed | Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) |
| NCT05035407 results posted | 10000045 000045-C | Ph 1 | terminated | T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers |
| NCT07173179 PEIR-PEP | Rectal NSAID vs Epi injection | Ph 4 | completed | Papillary Epinephrine Injection vs Rectal Indomethacin |
| NCT06572917 SPIN | H24-02525 | Ph 2 | not yet recruiting | Single-dose Prophylactic INdomethacin in Extremely Preterm Infants |
| NCT06253702 results posted | 2023-0548 1R01HL150361-01, EDUC/KINESIOLOGY | Ph 4 | completed | Brain Blood Flow Responses to Stress: Sex Differences |
| NCT03267680 results posted | 5GYN-16-2 NCI-2017-01402, 5GYN-16-2 | Ph 2 | terminated | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 |
| NCT03713879 | StentvsNSAID | Ph 3 | recruiting | Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis |
| NCT03648437 PAI | 38/2018 | Ph 1 | terminated | Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus |
| NCT04207060 results posted | 18-008193 R21DK117212 | Ph 1, Ph 2 | completed | Trial of Indomethacin in Chronic Pancreatitis |
| NCT02609386 INSPIRE results posted | IRX-2 2015-A | Ph 2 | completed | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity |
| NCT05999708 | 218680 | Ph 1 | withdrawn | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants |
| NCT01265849 IT-MATTERS results posted | CS001P3 2010-019952-35 | Ph 3 | completed | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity |
| NCT02849990 results posted | 9628 NCI-2016-01027, 9628 | Ph 2 | completed | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy |
| NCT02438371 results posted | HSC-MS-15-0134 | Ph 4 | terminated | Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor |
| NCT02221219 results posted | HD070792 R01HD070792 | Ph 1, Ph 2 | completed | Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury |
| NCT02692391 results posted | STUDY19050212 | Ph 3 | completed | A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis |
| NCT00549549 results posted | A3191219 | Ph 3 | completed | Celebrex In Acute Gouty Arthritis Study |
| NCT03473665 results posted | AAAR3505 | Ph 4 | terminated | Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis |
| NCT03537144 | 16-04411-FB | Ph 3 | terminated | Acetaminophen vs Indomethacin in Treating hsPDA |
| NCT02603822 | 15-003603 | Ph 1 | completed | Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability |
| NCT03712241 | K-285-101 | Ph 1 | completed | Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults |
| NCT02641561 IND+LRPEP results posted | 14-091 | Ph 3 | completed | Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis |
| NCT01848665 | EEL 073.3 | Ph 4 | completed | The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress |
| NCT01830335 | 12-167 | Ph 4 | completed | Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress |
| NCT03261635 | NSAIDs_02 | Ph 4 | completed | Ranibizumab Plus Indomethacin |
| NCT01719926 PIFA | NL40487.041.12 | Ph 1 | completed | Phase I Platinum Based Chemotherapy Plus Indomethacin |
| NCT01733485 EFADA | U10HL098177 | Ph 1 | completed | Electrophilic Fatty Acid Derivatives in Asthma |
| NCT00855920 SURGE results posted | IL1T-GA-0814 | Ph 3 | completed | Study Utilizing Rilonacept in Gout Exacerbations |
| NCT01774604 results posted | CPHS#23749 | Ph 3 | terminated | Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis |
| NCT00750581 | RT734510 | Ph 2, Ph 3 | terminated | An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants |
| NCT02577809 | M141181 | Ph 4 | completed | Intrathecal Opioid Study |
| NCT01957215 results posted | 202177 RH01778 | Ph 4 | completed | Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief |
| NCT02110810 Indomethacin | Indomethacin-2014-02 | Ph 3 | completed | Indomethacin Decreases Post-ERCP Pancreatitis |
| NCT01577121 INDOGEST | INDOGEST | Ph 2 | completed | Evaluation of the Use of Indomethacin as Co-treatment in Women With Preterm Labor and High Risk of Intraamniotic Inflammation |
| NCT01626118 results posted | IND3-10-06 | Ph 3 | completed | Study of Indomethacin Capsules to Treat Pain Following Bunionectomy |
| NCT01543685 results posted | IND3-08-04b | Ph 3 | completed | Study of Indomethacin Capsules to Treat Pain Following Bunionectomy |
| NCT00820612 results posted | HUM00022847 | Ph 4 | terminated | Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients |
| NCT01070745 | chammerman3 | Ph 2 | withdrawn | Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) |
| NCT01280006 | UC-MMHAP-COX-IH-2010001 | Ph 1, Ph 2 | completed | Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans |
| NCT07661498 | 25-44446 | Ph 4 | not yet recruiting | Indomethacin for Biliary ERCP Patients |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
INDOMETHACIN FDA Label Details
Looking for the branded version?
INDO-LEMMON
Full clinical data, patents, trials, and competitive landscape for indomethacin.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.